Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy

Inclusion Criteria:

1. Be ≥ 21 and ≤ 85 years of age.

2. Have documented CAD (> 70% lesion in at least 1 epicardial vessel) with evidence ofmyocardial injury, LV dysfunction, and clinical evidence of HF.

3. Have a "detectable" area of myocardial injury defined as ≥ 5% LV involvement (infarct volume) and any subendocardial involvement by MRI.

4. Have an EF ≤ 40% by MRI.

5. Be receiving guideline driven medical therapy for HF (beta blockers, diuretics, ACEinhibitors or ARBs, or ARNIs, aldosterone antagonists, hydralazine isosorbide,sodium-glucose transporter 2 inhibitors) ) at stable, maximally tolerated doses for ≥ 1 month prior to consent. "Stable" is defined as stable dose with no changes for 30 days after last dose adjustment. For beta blockade "stable" is defined as nogreater than a 50% reduction in dose or no more than a 100% increase in dose.

6. Have NYHA class I, II or III symptoms of HF (see Appendix A)

7. If a female of childbearing potential, be willing to use one form of birth controlfor the duration of the study and undergo a serum pregnancy test at baseline andwithin 36 hours prior to infusion

Exclusion Criteria:

1. Indication for standard of care surgery (including valve surgery, placement of leftventricular assist device, or imminent heart transplantation), coronary arterybypass grafting (CABG) procedure, and/or percutaneous coronary intervention (PCI)for the treatment of ischemic and/or valvular heart disease. Subjects who require orundergo PCI should undergo these procedures a minimum of 3 months in advance ofrandomization. Subjects who require or undergo CABG should undergo these proceduresa minimum of 3 months in advance of randomization. In addition, subjects who developa need for revascularization following enrollment should undergo revascularizationwithout delay. Indication for imminent heart transplantation is defined as a highlikelihood of transplant prior to collection of the 12 month study endpoint.Candidates cannot be UNOS 1A or 1B, and they must have documented a low probabilityof being transplanted.

2. Severe valvular (any valve) insufficiency and/or regurgitation within 12 months ofconsent

3. History of ischemic or hemorrhagic stroke within 90 days of consent

4. Presence of a pacemaker and/or implantable cardiac device (ICD) generator with anyof the following limitations/conditions:

• manufactured before the year 2000

• leads implanted < 6 weeks prior to consent

• non transvenous epicardial or abandoned leads

• subcutaneous ICDs (if not MRI compatible)

• leadless pacemakers

• any other condition that, in the judgment of device trained staff, would deeman MRI contraindicated

5. Pacemaker dependence with an ICD (Note: pacemaker dependent candidates without anICD are not excluded)

6. A cardiac resynchronization therapy (CRT) device implanted less than 3 months priorto consent.

7. Other MRI contraindications (e.g. patient body habitus incompatible with MRI)

8. An appropriate ICD firing or anti tachycardia pacing (ATP) for ventricularfibrillation or ventricular tachycardia within 30 days of consent

9. Ventricular tachycardia ≥ 20 consecutive beats without an ICD within 3 months ofconsent, or symptomatic Mobitz II or higher degree atrioventricular block without afunctioning pacemaker within 3 months of consent

10. Evidence of active myocarditis

11. Baseline glomerular filtration rate (eGFR) < 35 ml/min/1.73m2

12. Blood glucose levels (HbA1c) >10%

13. Hematologic abnormality evidenced by hematocrit < 25%, white blood cell < 2,500/ulor platelet count < 100,000/ul

14. Liver dysfunction evidenced by enzymes (AST and ALT) ˃ 3 times the ULN.

15. HIV and/or active HBV or HCV

16. Known history of anaphylactic reaction to penicillin or streptomycin

17. Received gene or cell based therapy from any source within the previous 12 months.

18. History of malignancy within 2 years (i.e., subjects with prior malignancy must bedisease free for 2 years), excluding basal cell carcinoma and cervical carcinoma insitu which have been definitively treated.

19. Condition that limits lifespan to < 1 year

20. History of drug abuse (illegal "street" drugs except marijuana, or prescriptionmedications not being used appropriately for a pre-existing medical condition) oralcohol abuse (≥ 5 drinks/day for ˃ 3 months), or documented medical, occupational,or legal problems arising from the use of alcohol or drugs within the past 12months.

21. Participation in an investigational therapeutic or device trial within 30 days ofconsent

22. Cognitive or language barriers that prohibit obtaining informed consent or any studyelements

23. Pregnancy or lactation or plans to become pregnant in the next 12 months.

24. Any other condition that, in the judgment of the Investigator or Sponsor, wouldimpair enrollment, study product administration, or follow up.